Dengue virus serotype 3 polyprotein (DENV-3 antigens)

Dengue virus serotype 3 (DENV-3) antigens are derived from a single large polyprotein that is post-translationally cleaved into three structural proteins (C, prM, and E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [UniProt: P27915]. The Envelope (E) protein is the primary surface antigen responsible for host cell receptor binding and membrane fusion, making it the central target for vaccine-induced immunity [CDC, 2024]. Non-structural proteins like NS3 and NS5 function as essential enzymes for viral RNA replication and polyprotein processing, serving as key targets for direct-acting antiviral development [Nature Reviews Drug Discovery, 2021]. NS1 is a secreted glycoprotein that acts as a potent immunogen and a critical factor in pathogenesis, specifically contributing to the vascular leakage observed in severe dengue cases [WHO, 2023]. Therapeutic strategies focusing on these antigens include tetravalent live-attenuated vaccines, such as Qdenga, which aim to provide balanced protection across all four dengue serotypes [Takeda, 2023]. A significant challenge in targeting DENV-3 antigens is antibody-dependent enhancement (ADE), where sub-neutralizing antibodies from a previous infection or vaccination can facilitate viral entry into Fc-receptor-bearing cells, potentially exacerbating disease severity.

Other names

Dengue virus type 3 antigensDENV-3 proteinsDengue virus 3 polyproteinDENV-3 structural and non-structural proteins

Vaccines induce neutralizing antibodies primarily against the Envelope (E) protein to block viral attachment and fusion with host cell membranes [Nature Reviews Microbiology, 2020]. Small-molecule antivirals target non-structural proteins, such as the NS3 protease to prevent polyprotein cleavage or the NS4B protein to disrupt the viral replication complex [Antiviral Research, 2022].